At-Home Administration

BENLYSTA for subcutaneous* (SC) use is an at-home injection for adults and children ages 5 years and older. This injection can be given after you or a caregiver are trained by a healthcare provider.

* Prefilled syringe has not been studied in children less than 18 years of age.

The BENLYSTA Autoinjector

The BENLYSTA Autoinjector is one of the ways you can take BENLYSTA in the comfort of your own home.

Close up of the BENLYSTA Autoinjector held with two hands

What to know about at-home administration

Where it happens

You can use the autoinjector or prefilled syringe in the comfort of your own home.

How long the injection takes

The BENLYSTA Autoinjector may take up to 15 seconds to complete.

How often it happens

BENLYSTA dosing and schedule vary depending on age and weight. See below for more details.

Understand how at-home administration works.

How to use the BENLYSTA Autoinjector

Your doctor will show you how to take BENLYSTA safely and effectively. Use this video as a guide for self-injection with the autoinjector.

Step-by-step instructions

See the instructions for at-home administration below or download the full Instructions for Use.

    Read the BENLYSTA Injection Guide

    BENLYSTA at-home dosing schedules

    Use BENLYSTA on the same day each week or the same day every 2 weeks, as you discussed with your healthcare provider. Whether you take BENLYSTA once per week or every 2 weeks, plan on taking it on the same day of the week.

    View Medication Guide

    Dosing Schedules

      It can take some time before you may notice any changes from treatment with BENLYSTA. Talk to your doctor about what you can expect while on treatment.

      Filling your BENLYSTA at-home prescription

      BENLYSTA is available for at-home use as an autoinjector or a prefilled syringe (for adults only) and will be filled by a specialty pharmacy. The process for filling your prescription is the same for the autoinjector or prefilled syringe.

        How should I store BENLYSTA Autoinjectors?

        Store autoinjectors and prefilled syringes in the refrigerator at 36°F to 46°F (2°C to 8°C) until 30 minutes before use.

         

        • Keep BENLYSTA SC (subcutaneous) in the original package until time of use to protect from light
        • Do not shake
        • Do not freeze
        • Keep away from heat and sunlight
        • Do not use or place back in the refrigerator if left at room temperature for more than 12 hours
        • Keep out of the reach of children

        What to expect on BENLYSTA

        Morgan, a real BENLYSTA patient compensated by GSK, shares her autoinjector experience.

        Explore support for BENLYSTA

        Help with benefits and savings

        Understand your insurance coverage for BENLYSTA and receive copay assistance if you qualify.

        Text reminders

        Get convenient notifications via SMS to be sure you receive your treatment on time.

        Helpful resources

        Stay informed and empowered with useful content tailored to your needs.

        Approved Use & Safety Info

        Approved Use

        Important Safety Information

        Approved Use

        What is BENLYSTA?

        BENLYSTA is a prescription medicine used to treat adults and children 5 years of age and older with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (LN) (lupus-related kidney inflammation) who are receiving other lupus medicines. It is not known if BENLYSTA is safe/effective in people with severe active central nervous system lupus.

         

        It is not known if BENLYSTA is safe and effective for use in children less than 5 years of age.

         

        It is not known if BENLYSTA, given under the skin (subcutaneously), is safe and effective for use in children who weigh less than 33 pounds (15 kilograms).

        Important Safety Information

        Do not use BENLYSTA if you are allergic to belimumab or any ingredients in BENLYSTA.

         

        The most important information about BENLYSTA

         

        Immunosuppressive agents, including BENLYSTA, can cause serious side effects. Some of these may cause death.

        • Infections: fever, chills, pain or burning with urination, urinating often, coughing up mucus, or warm, red, or painful skin or sores on your body. Infections could be serious, leading to hospitalization or death.
        • Allergic (hypersensitivity) reactions: itching, swelling of the face, lips, mouth, tongue, or throat, trouble breathing, anxiousness, low blood pressure, dizziness or fainting, headache, nausea, or skin rash. Serious allergic reactions can happen the day of, or in days after, receiving BENLYSTA and may cause death.
        • Mental health problems and suicide: thoughts of suicide or dying, attempt to commit suicide, trouble sleeping (insomnia), new or worse anxiety or depression, acting on dangerous impulses, other unusual changes in your behavior or mood, or thoughts of hurting yourself or others.

         

        Before receiving BENLYSTA, discuss with your healthcare provider if you:

        • think you have an infection or have infections that keep coming back. Do not use BENLYSTA if you have an infection unless your healthcare provider tells you to.
        • have or have had mental health problems such as depression or thoughts of suicide.
        • have recently received or may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.
        • are taking any medicines, including prescription, over-the-counter, vitamins, and herbal supplements.
        • are allergic to other medicines.
        • are receiving other biologic medicines.  
        • have or have had any type of cancer.
        • have any other medical conditions.
        • are pregnant or plan to become pregnant. It is unknown if BENLYSTA will harm your unborn baby. Talk to your healthcare provider about whether to prevent pregnancy while on BENLYSTA. If you choose to prevent pregnancy, you should use an effective method of birth control for at least 4 months after the final dose of BENLYSTA.
        • become pregnant while receiving BENLYSTA, talk to your healthcare provider about enrolling in the BENLYSTA Pregnancy Registry. You can enroll in this registry by calling 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/benlysta-belimumab/.
        • are breastfeeding or plan to breastfeed. It is unknown if BENLYSTA passes into your breast milk.

         

        Possible side effects of BENLYSTA

        • Progressive multifocal leukoencephalopathy (PML). PML is a serious and life-threatening brain infection. PML can result in death or severe disability. Tell your healthcare provider right away if you notice any new or worsening medical problems: memory loss, trouble thinking, dizziness or loss of balance, difficulty talking or walking, or loss of vision.
        • Cancer. Medicines that affect the immune system, including BENLYSTA, may increase your risk of certain cancers.

         

        The most common side effects of BENLYSTA are nausea, diarrhea, fever, stuffy or runny nose and sore throat, persistent cough, trouble sleeping, leg or arm pain, depression, headache, and pain, redness, itching, or swelling at the site of injection (when given subcutaneously). These are not all the possible side effects of BENLYSTA. Call your doctor for medical advice about side effects.

         

        Please see Prescribing Information and Medication Guide for BENLYSTA.

        You are encouraged to report negative side effects of prescription drugs to the FDA.
        Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
        GSK Help Center logo

        Explore the GSK Help Center website to find customer service support and contact information.

        Pay as little as zero dollars

        Eligible commercially insured patients may pay as little as $0 for BENLYSTA, subject to program maximums.*

        *Program annual maximums apply. Visit BenlystaCopayProgram.com for information about eligibility and full program terms and conditions.